amantadine has been researched along with Infections, Coronavirus in 9 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "Facing the outbreak of coronavirus disease 2019 (COVID-19) pandemic, there is an urgent need to find protective or curable drugs to prevent or to stop the course of the coronavirus SARS-CoV-2 infection." | 5.56 | Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. ( Grieb, P; Rejdak, K, 2020) |
| "Respiratory viruses (influenza, parainfluenza, respiratory syncytial virus, coronavirus, human metapneumovirus, and rhinovirus) represent the most common causes of respiratory viral infections in immunocompromised patients." | 2.55 | Antiviral therapy for respiratory viral infections in immunocompromised patients. ( Ariza-Heredia, EJ; Chemaly, RF; Shahani, L, 2017) |
| "Amantadine was approved by the US Food and Drug Administration in 1968 as a prophylactic agent for influenza and later for Parkinson's disease." | 1.56 | Amantadine disrupts lysosomal gene expression: A hypothesis for COVID19 treatment. ( Polymeropoulos, MH; Przychodzen, BP; Smieszek, SP, 2020) |
| "Facing the outbreak of coronavirus disease 2019 (COVID-19) pandemic, there is an urgent need to find protective or curable drugs to prevent or to stop the course of the coronavirus SARS-CoV-2 infection." | 1.56 | Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. ( Grieb, P; Rejdak, K, 2020) |
| "The International Society for Influenza and other Respiratory Virus Diseases (isirv) held its 4th Antiviral Group Conference at the University of Texas on 2-4 June, 2015." | 1.43 | Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses. ( Fry, AM; McKimm-Breschkin, JL, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 7 (77.78) | 2.80 |
| Authors | Studies |
|---|---|
| Smieszek, SP | 1 |
| Przychodzen, BP | 1 |
| Polymeropoulos, MH | 1 |
| Abreu, GEA | 1 |
| Aguilar, MEH | 1 |
| Covarrubias, DH | 1 |
| Durán, FR | 1 |
| Rejdak, K | 1 |
| Grieb, P | 1 |
| Cortés Borra, A | 1 |
| Tipton, PW | 1 |
| Wszolek, ZK | 1 |
| Wiwanitkit, V | 1 |
| Aranda-Abreu, GE | 1 |
| McKimm-Breschkin, JL | 1 |
| Fry, AM | 1 |
| Shahani, L | 1 |
| Ariza-Heredia, EJ | 1 |
| Chemaly, RF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Amantadine for COVID-19: A Randomized, Placebo Controlled, Double-blinded, Clinical Trial[NCT04894617] | Phase 3 | 226 participants (Anticipated) | Interventional | 2021-06-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for amantadine and Infections, Coronavirus
| Article | Year |
|---|---|
Antiviral therapy for respiratory viral infections in immunocompromised patients.
Topics: Acids, Carbocyclic; Amantadine; Antiviral Agents; Coronavirus Infections; Cyclopentanes; Guanidines; | 2017 |
8 other studies available for amantadine and Infections, Coronavirus
| Article | Year |
|---|---|
Amantadine disrupts lysosomal gene expression: A hypothesis for COVID19 treatment.
Topics: Amantadine; Antiviral Agents; Betacoronavirus; Cathepsin B; Cathepsin L; Cell Line; Coronavirus Infe | 2020 |
Amantadine as a drug to mitigate the effects of COVID-19.
Topics: Amantadine; Betacoronavirus; Coronavirus Envelope Proteins; Coronavirus Infections; COVID-19; COVID- | 2020 |
Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment.
Topics: Adamantane; Adult; Aged; Aged, 80 and over; Amantadine; Asymptomatic Infections; Betacoronavirus; Co | 2020 |
Does amantadine have a protective effect against COVID-19?
Topics: Amantadine; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Pneumonia, Viral; | 2020 |
Response to "Does amantadine have a protective effect against COVID-19?"
Topics: Amantadine; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Pneumonia, Viral; | 2020 |
Amantadine, COVID-19 and Parkinsonism.
Topics: Amantadine; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Parkinsonian Disor | 2020 |
Response to: Amantadine, COVID-19 and Parkinsonism.
Topics: Amantadine; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Parkinsonian Disor | 2020 |
Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses.
Topics: Amantadine; Antibody-Dependent Enhancement; Antiviral Agents; Coronavirus Infections; Drug Resistanc | 2016 |